Oncology Data Advisor™ · Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  ...

Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss his presentation on the results of research regarding momelotinib in treatment of myelofibrosis. This podcast episode was recorded live by Oncology Dat...

Oncology Data Advisor™ · Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting. &...

Oncology Data Advisor™ · Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, presented a late-breaking abstract on the BMT CTN 1703 trial of post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis after allogenic hematopoieti...

Oncology Data Advisor™ · Subsequent Treatment After CAR T-Cell Therapy in Large B-Cell Lymphoma With Armin Ghobadi, MD Recently, at the American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Armin Ghobadi, an Associate Professor at the Washington University School of Medicine, Siteman Cancer Center, sat down with Oncology Data Advisor to enlighten us about his research and presentation regarding the ZUMA-7 trial, in which he discusses the outcomes of subsequent anti...

Oncology Data Advisor™ · Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.  ...

Oncology Data Advisor™ · Improving the Standard of Care for Advanced Hodgkin Lymphoma With Mitul Gandhi, MD At the recent American Society of Hematology (ASH) Annual Meeting, updated results were presented for the SGN35-027 study of brentuximab vedotin plus nivolumab and chemotherapy for advanced-stage classical Hodgkin lymphoma. One of its authors, Dr. Mitul Gandhi of Virginia Cancer Specialists, sat down with Oncology Data Advisor while there to discuss the importance of the trial...

Oncology Data Advisor™ · Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL)...

Oncology Data Advisor™ · Association of Socioeconomic Status With Adherence and Survival in Myeloma: Leon Bernal-Mizrachi, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Leon Bernal-Mizrachi, MD, an Associate Professor of Medicine in the Department of Hematology and Oncology at the Emory University School of Medicine, sat down with Oncology Data Advisor to discuss his research and presentation regarding association of socioeconomic status with a...

Oncology Data Advisor™ · Advancing the Careers of Women in Hematology With Ariela Marshall, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ariela Marshall, MD, Director of the Women's Hemostasis and Thrombosis Program and Associate Professor of Clinical Medicine at Penn Medicine, sat down with Oncology Data Advisor to talk about the ASH Women in Hematology Working Group, a group committed to career advances and leadership opportunities for women in hematology....

Oncology Data Advisor™ · Factors Leading to Black Patient Disparities in Hematology Trials With Shakira Grant, MBBS At the recent American Society of Hematology (ASH) Annual Meeting, Shakira J. Grant, MBBS, an Assistant Professor of Medicine at the University of North Carolina at Chapel Hill, sat down with Oncology Data Advisor to discuss her research she presented, "If You Don't Trust Your Doctor That Much…You'd Feel Less Confident Doing a Research Study": Factors Influencing Black...

Oncology Data Advisor™ · Making Health Care Accessible for Acute Myeloid Leukemia Patients With Ian Bouligny, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Ian Bouligny, Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center, spoke with Oncology Data Advisor about his abstract regarding health care disparities faced by Black patients with acute myeloid leukemia (AML). Dr. Bouligny explains the factors that contribute to tr...

Oncology Data Advisor™ · Creating Valuable Education for the Hematology/Oncology Fellow: Ronak Mistry and Vivek Patel At the 2022 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Dr. Ronak Mistry and Dr. Vivek Patel, Clinical Fellows in Medicine at Vanderbilt University and hosts of The Fellow on Call podcast. Dr. Mistry and Dr. Patel share their passion for creating education geared towards fellows and the valuable experience of attending ASH...

Oncology Data Advisor™ · Dynamic Risk Classification of Smoldering Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Luis Gerardo Rodríguez-Lobato, MD, PhD, Specialist in Hematopoietic Stem Cell Transplant and Researcher at the Hospital Clínic de Barcelona and barnaclínic+, sat down with Oncology Data Advisor to discuss his research regarding dynamic risk classification for patients with smoldering multiple ...

Oncology Data Advisor™ · Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM ...

Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to discuss the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented. Dr. Raje elaborates on the efficacy and safety of th...

Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chi...

Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of ta...

Oncology Data Advisor™ · Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the...

Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation. This podcast episode was recorded live by O...

Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;...

Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributi...

In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) ...

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in ...

Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment ...

Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers led by Dr. Sumit Gupta of the University of Toronto investigated the impact of race, ethnicity, and socioeconomic status among young patients with ALL ...

For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Jerome Goldschmidt, medical oncologist at Blue Ridge Cancer Care and the ...

For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy, in this setting. Dr. Kamdar recently pres...

Compared with the non-Hispanic White population, Hispanic and Black adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) experience significantly inferior outcomes. In an analysis of the CALGB 10403 AYA trial presented at the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Lori Muffly, Associate Professor of Medicine at Stanford University, investigated racial and ethnic disparities in cl...

One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg School of Medicine, shared her thoughts on strategies for remedying these disparities so that more inclusive care can be provided for patients with h...

While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...

For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for this population. In this interview, one of the study's investigators, Dr. John Burke of Rocky Mountain Cancer Centers and the U...

For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Steven M. Horwitz, medical oncologist at Memorial Sloan Kettering Cancer Center, investigated the efficacy of the phosphoinositide-3-kinase inhibitor du...

For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Mikkael A. Sekeres, Professor of Medicine and Chief of the Division of Hematology at the Univer...

Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the hematologic malignancy setting was previously unknown. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting &...

While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through inpatient admission for frequent monitoring; however, an onsite hospital stay can create a significant burden for the patient. As part of a study recent...

i3 Health's study focusing on the effectiveness of an online continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of therapeutic advances in T-cell lymphoma (TCL) has been published as a 63rd American Society of Hematology (ASH) Annual Meeting & Exposition online abstract. ...